2 completed, 2 not yet recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Type2diabetes: new trials by email Literature Review of Type2diabetes trials Research Report on Type2diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Caloric Restriction, Hyperglycemic clamp - Type2diabetes | Phase 2 | Not yet recruiting | Adrian Vella | 20 | 2027-12-15 | 2026-10-28 |
| The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans Exendin 9-39, Saline - Genetic Predisposition, Type2diabetes | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-10-01 | 2026-01-30 |
| Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients Fuling Yunhua Granules, Dihuang Baoyuan Granules, Fuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placebo - Diabetes Mellitus, Type 2, Diabetes | Phase 2 | Completed | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | 95 | 2024-07-31 | 2026-10-05 |
| NAD Augmentation in Diabetes Kidney Disease Investigational Product - MIB 626, Placebo - Type2diabetes, Diabetic Kidney Disease | Phase 2 | Recruiting | Brigham and Women's Hospital | 156 | 2023-04-13 | 2026-04-13 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-11-04 |
Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Fatty Liver (2) · Insulin Resistance (2) · Diabetic Nephropathies (1) · Genetic Predisposition to Disease (1) · Kidney Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Glucose Metabolism Disorders (4) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Digestive System Diseases (2) · Endocrine System Diseases (2) · Hyperinsulinism (2) · Liver Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Diabetes Complications (1) · Disease Attributes (1) · Disease Susceptibility (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1)
Caloric Restriction (1) · Glucagon (1) · Sodium Chloride (1) · exendin (9-39) (1)
Adrian Vella (2) · Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (1) · Brigham and Women's Hospital (1) · Mayo Clinic (1)
United States (4) · China (1)
Adrian Vella (2) · Adrian Vella, MD (1) · Shalender Bhasin, MD (1)
R01DK116231 (1)